This is a news story, published by Ars Technica, that relates primarily to FDA news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
tirzepatide drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest FDA news, pharmacies news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
compounding pharmaciesArs Technica
ā¢
78% Informative
FDA reverses course on decision to take popular weight-loss and diabetes drugs off of shortage list.
Compounding pharmacies sued the FDA over its October 2 announcement that there was no longer a shortage of tirzepatide drugs.
Compounders were immediately barred from making any more of the lucrative drugs and had 60 days to fulfill existing orders.
In a court filing Friday , the FDA appeared to back down, requesting that the lawsuit be placed on hold.
VR Score
77
Informative language
76
Neutral language
36
Article tone
informal
Language
English
Language complexity
71
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links